Thus, together with loss of CCR7, SELL (lymph-node homing) and CLA (skin homing) the increased β7 integrin, ITGA4 and CXCR1 gene expression suggests a globally altered trafficking profile biased towards preferential gut homing, supporting potential clinical utility for the treatment of an autoimmune disorder of the gut. Here, SELL is linked to autoimmune disease.